Cadrenal Therapeutics (CVKD) Proxy filing summary

Executive summary

• Annual meeting scheduled for September 24, 2026, with virtual participation available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by September 23, 2026.

• Voting can be completed online, by phone, or by requesting paper/email materials.

Voting matters and shareholder proposals

• Election of Quang X. Pham as director is up for shareholder vote.

• Ratification of WithumSmith + Brown, PC as independent auditor for fiscal year ending December 31, 2026.

• Proposal to amend the 2022 Successor Equity Incentive Plan to increase available shares for awards to 1,000,000.

• Approval sought for issuance of up to 960,000 shares upon exercise of Series C-1 warrants from a July 2026 private placement.

• Proposal to allow adjournment of the meeting if more time is needed for proxy solicitation on key proposals.

Board of directors and corporate governance

• Board recommends approval of all proposals presented for the 2026 annual meeting.

• Only one director nominee, Quang X. Pham, is listed for election.